Jiazhao Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jiazhao Yang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Baoliang Lu
Department of Trauma Orthopedics Affiliated Anhui Provincial Hospital of Bengbu Medical University Bengbu 233030 China
1 shared publicationBin Xu
Department of Sports Injury and Arthroscopic Surgery The First Affiliated Hospital of Anhui Medical University Hefei 230001 China
1 shared publicationJunchen Zhu
Department of Orthopedics The Second Affiliated Hospital of Anhui University of Chinese Medicine Anhui University of Chinese Medicine Hefei 230061 China
1 shared publicationKai Xie
Department of Orthopedics Northern Jiangsu People's Hospital Clinical Teaching Hospital of Medical School Nanjing University Nanjing 225001 China
1 shared publicationLei Xu
Department of Sports Injury and Arthroscopic Surgery The First Affiliated Hospital of Anhui Medical University Hefei 230001 China
1 shared publicationShiyuan Fang
Department of Trauma Orthopedics The First Affiliated Hospital of the University of Science and Technology of China Hefei 230001 China
1 shared publication
Latest Publications
- 19 November 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (3) , e2403318
Photothermal Nano‐Immunotherapy Against Methicillin‐Resistant Staphylococcus aureus (MRSA) Biofilm Infections
Methicillin‐resistant Staphylococcus aureus (MRSA) biofilm infections are a prevalent type of biofilm‐associated infection with a poor prognosis and antibiotic resistance. The senescence of immune cells in the immune microenvironment contributes to biofilm formation. In this study, Ti₃C₂ MXene‐PVA nanosheets loaded with metformin (Met@TiC) are developed for the treatment of MRSA biofilm infections. Nanosheets utilize near‐infrared light to induce photothermal effects and provide direct bactericidal activity against biofilm structures. Met, which is known for its anti‐inflammatory and anti‐senescence properties, modulates immune responses by revitalizing the function of senescent macrophages within the biofilm microenvironment, thereby enhancing their phagocytic and biofilm‐eradicating capabilities. The efficacy of this nanoplatform both in vitro and in an MRSA biofilm infection mouse model, demonstrating its potential as a photothermal nanoimmunotherapy for combating MRSA biofilm infections is validated. In summary, the Met@TiC nanoplatform offers a significant alternative to clinical solutions for MRSA biofilm infections.
- 19 November 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (3) , e2403318
Photothermal Nano‐Immunotherapy Against Methicillin‐Resistant Staphylococcus aureus (MRSA) Biofilm Infections
Methicillin‐resistant Staphylococcus aureus (MRSA) biofilm infections are a prevalent type of biofilm‐associated infection with a poor prognosis and antibiotic resistance. The senescence of immune cells in the immune microenvironment contributes to biofilm formation. In this study, Ti₃C₂ MXene‐PVA nanosheets loaded with metformin (Met@TiC) are developed for the treatment of MRSA biofilm infections. Nanosheets utilize near‐infrared light to induce photothermal effects and provide direct bactericidal activity against biofilm structures. Met, which is known for its anti‐inflammatory and anti‐senescence properties, modulates immune responses by revitalizing the function of senescent macrophages within the biofilm microenvironment, thereby enhancing their phagocytic and biofilm‐eradicating capabilities. The efficacy of this nanoplatform both in vitro and in an MRSA biofilm infection mouse model, demonstrating its potential as a photothermal nanoimmunotherapy for combating MRSA biofilm infections is validated. In summary, the Met@TiC nanoplatform offers a significant alternative to clinical solutions for MRSA biofilm infections.